Apyx Medical Corporation provided earnings guidance for the year ending December 31, 2024. For the year, the company expects Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | -2.03% | +9.85% | -44.66% |
Apr. 05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
Apr. 01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.66% | 50.23M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024